Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Jan;59(1):126–130. doi: 10.1128/iai.59.1.126-130.1991

Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model.

J R Izbicki 1, C Raedler 1, A Anke 1, P Brunner 1, M Siebeck 1, E Leinisch 1, R Lüttiken 1, G Ruckdeschel 1, D K Wilker 1, L Schweiberer 1, et al.
PMCID: PMC257715  PMID: 1987024

Abstract

In a porcine model of pneumococcal septicemia, animals were pretreated with 1 mg of liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (MTP-PE) or with liposomes alone. After 24 h each animal received an injection of either 10(9) or 10(10) pneumococcal serotype 6B cells. MTP-PE pretreatment resulted in less pronounced leukocytopenia, with a nadir of 6,700 (versus 4,100) leukocytes per mm3 after injection of 10(9) bacteria and a nadir of 4,400 (versus 3,800) leukocytes per mm3 after injection of 10(10) bacteria. At the same time bacterial clearance was substantially improved by MTP-PE pretreatment. Finally, pretreatment with MTP-PE dramatically reduced mortality; the average death rates for both series of animals used were 55% for liposome-pretreated animals and 3% for animals pretreated with MTP-PE-containing liposomes. These results in a preclinical model suggest that treatment with MTP-PE-containing liposomes might be beneficial in controlling septicemia in patients at risk.

Full text

PDF
126

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  2. Bone R. C., Fisher C. J., Jr, Clemmer T. P., Slotman G. J., Metz C. A., Balk R. A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987 Sep 10;317(11):653–658. doi: 10.1056/NEJM198709103171101. [DOI] [PubMed] [Google Scholar]
  3. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Endres S., Ghorbani R., Lonnemann G., van der Meer J. W., Dinarello C. A. Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol. 1988 Dec;49(3):424–438. doi: 10.1016/0090-1229(88)90130-4. [DOI] [PubMed] [Google Scholar]
  5. Fidler I. J., Sone S., Fogler W. E., Barnes Z. L. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1680–1684. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fogler W. E., Wade R., Brundish D. E., Fidler I. J. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice. J Immunol. 1985 Aug;135(2):1372–1377. [PubMed] [Google Scholar]
  7. Gangemi J. D., Nachtigal M., Barnhart D., Krech L., Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis. 1987 Mar;155(3):510–517. doi: 10.1093/infdis/155.3.510. [DOI] [PubMed] [Google Scholar]
  8. Izbicki J. R., Ziegler-Heitbrock H. W., Meier M., Lütticken R., Wilker D. K., Siebeck M., Scheuber H. P., Schweiberer L. The impact of splenectomy on antibody response in the porcine model. J Clin Lab Immunol. 1989 Sep;30(1):13–19. [PubMed] [Google Scholar]
  9. Kaufmann S. H. Immunity to bacteria and fungi. Curr Opin Immunol. 1989 Feb;1(3):431–440. doi: 10.1016/0952-7915(88)90023-4. [DOI] [PubMed] [Google Scholar]
  10. Koff W. C., Fidler I. J., Showalter S. D., Chakrabarty M. K., Hampar B., Ceccorulli L. M., Kleinerman E. S. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 1;224(4652):1007–1009. doi: 10.1126/science.6426057. [DOI] [PubMed] [Google Scholar]
  11. Leonard A. S., Giebink G. S., Baesl T. J., Krivit W. The overwhelming postsplenectomy sepsis problem. World J Surg. 1980 Jul;4(4):423–432. doi: 10.1007/BF02393164. [DOI] [PubMed] [Google Scholar]
  12. Murray J. L., Kleinerman E. S., Cunningham J. E., Tatom J. R., Andrejcio K., Lepe-Zuniga J., Lamki L. M., Rosenblum M. G., Frost H., Gutterman J. U. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989 Dec;7(12):1915–1925. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
  13. Old L. J. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630–632. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
  14. Oppenheim J. J., Togawa A., Chedid L., Mizel S. Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol. 1980 Mar 1;50(1):71–81. doi: 10.1016/0008-8749(80)90007-6. [DOI] [PubMed] [Google Scholar]
  15. Saiki I., Milas L., Hunter N., Fidler I. J. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Cancer Res. 1986 Oct;46(10):4966–4970. [PubMed] [Google Scholar]
  16. Sone S., Mutsuura S., Ogawara M., Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol. 1984 Apr;132(4):2105–2110. [PubMed] [Google Scholar]
  17. Sone S., Tandon P., Utsugi T., Ogawara M., Shimizu E., Nii A., Ogura T. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Int J Cancer. 1986 Oct 15;38(4):495–500. doi: 10.1002/ijc.2910380407. [DOI] [PubMed] [Google Scholar]
  18. Thorens B., Mermod J. J., Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell. 1987 Feb 27;48(4):671–679. doi: 10.1016/0092-8674(87)90245-5. [DOI] [PubMed] [Google Scholar]
  19. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  20. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  21. Xu Z., Fidler I. J. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol Immunother. 1984;18(2):118–122. doi: 10.1007/BF00205745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ziegler-Heitbrock H. W., Möller A., Linke R. P., Haas J. G., Rieber E. P., Riethmüller G. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res. 1986 Nov;46(11):5947–5952. [PubMed] [Google Scholar]
  23. Ziegler-Heitbrock H. W. The biology of the monocyte system. Eur J Cell Biol. 1989 Jun;49(1):1–12. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES